Andere Sprachen ExpreS2ion Biotech Holding AB

Aktien

A2APAB

SE0008348262

EXPRS2

Verzögert Nasdaq Stockholm Andere Börsenplätze 11:13:58 12.06.2024			% 5 Tage	% 1. Jan.
1,042 ^SEK	-5,96 %		-23,94 %	-50,62 %

16.05.	ExpreS2ion Biotech Holding AB (publ) meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
16.04.	ExpreS2ion gibt den Abschluss der GLP-Sicherheitsstudie für den Brustkrebs-Impfstoffkandidaten ES2B-C001 (HER2-VLP) bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

ExpreS2ion CEO to BioStock: "Compelling preclinical package gives us confidence"	09:15
The subscription period in ExpreS2ion's rights issue begins today	08:46
ExpreS2ion to present in upcoming investor and scientific events	10.06.
ExpreS2ion publishes prospectus in connection with its rights issue of units	05.06.
Bulletin from the Annual General Meeting of ExpreS2ion Biotech Holding AB held on 5 June 2024	05.06.
ExpreS2ion Biotech : Interim report for January – March 2024 (Q1)	16.05.
ExpreS2ion announces financial results for the first quarter of 2024	16.05.
ExpreS2ion Biotech Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	16.05.
ExpreS2ion to present in spring investor events	15.05.
ExpreS2ion Biotech : Annual report 2023 including Auditor’s report	08.05.
ExpreS2ion annual report for 2023 published	08.05.
Notice to attend the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)	03.05.
ExpreS2ion announces a rights issue of units of approximately SEK 60 million	02.05.
ExpreS2ion to receive approximately SEK 22.5 million dividend payment from AdaptVac ApS	23.04.
ExpreS2ion changes dates for the annual general meeting and the publication of the annual report for 2023	16.04.
ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate	16.04.
ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate	16.04.
ExpreS2ion to present in investor and R&D events in March	15.04.
ExpreS2ion to present in investor and R&D events in March	29.02.
ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial	21.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen ExpreS2ion Biotech Holding AB

Aktien

A2APAB

SE0008348262

EXPRS2

Andere Sprachen

Filter